Breaking
extra newsTwitter has suspended President Donald Trump from its platform, the company said.. 13
extra newsFacebook CEO Mark Zuckerberg said in a post that the social media giant was bann.. 21
politics newsThis was after he beat Professor Aaron Mike Quaye, the Speaker of the Seventh Pa.. 18
politics newsNana Akufo-Addo took the Presidential Oath and the Oath of Allegiance administer.. 19
technology newsAn Elasticsearch database with over 380 million records, including login credent.. 41
science newsHe Jiankui, the Chinese researcher who stunned the world last year by announcing.. 48
  • Photo Gallery
  • Contact us
  • Login
  • Covid19 Cases
  • Confirmed
  • Deaths
  • Recovered
  • Recovery(%)
Weather Ghana, °C
392 954 118 1.9k
Show Menu
  • Home
  • News
    • Financial
    • Business
    • Social
    • Extra
    • Politics
    • Health
    • Education
    • Opinion
    • Religion
    • Science
    • Technology
  • Sports
  • Entertainment
    • Music
    • Movie
    • Gossip
  • Institutions
  • Blogs
  • Classifieds
    • Events
    • Auto
    • Real Estate
    • Announcement
  • Lifestyle
    • Gadgets
    • Recipes
  • Ghana
    • eDocuments
  • Jobs
  • Contact us

Antibody blocks infection by the SARS-CoV-2 in cells, scientists discover

Utrecht University 04 May 2020 339 news, science

SARS-CoV-2 concept illustration (stock image). Credit: © pinkeyes / Adobe Stock


Researchers at Utrecht University, Erasmus Medical Center and Harbour BioMed (HBM) today reported that they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells. The discovery, published online today in Nature Communications, is an initial step towards developing a fully human antibody to treat or prevent the respiratory disease COVID-19 caused by the novel coronavirus SARS-CoV-2.

The COVID-19 pandemic has spread rapidly across the globe infecting more than 3.3M people worldwide and killing more than 235,000 people so far.

"This research builds on the work our groups have done in the past on antibodies targeting the SARS-CoV that emerged in 2002/2003," said Berend-Jan Bosch, Associate Professor, Research leader at Utrecht University, and co-lead author of the Nature Communications study. "Using this collection of SARS-CoV antibodies, we identified an antibody that also neutralizes infection of SARS-CoV-2 in cultured cells. Such a neutralizing antibody has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus."

Dr. Bosch noted that the antibody binds to a domain that is conserved in both SARS-CoV and SARS-CoV-2, explaining its ability to neutralize both viruses. "This cross-neutralizing feature of the antibody is very interesting and suggests it may have potential in mitigation of diseases caused by future-emerging related coronaviruses."

"This discovery provides a strong foundation for additional research to characterize this antibody and begin development as a potential COVID-19 treatment," said Frank Grosveld, PhD. co-lead author on the study, Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam and Founding Chief Scientific Officer at Harbour BioMed. "The antibody used in this work is 'fully human,' allowing development to proceed more rapidly and reducing the potential for immune-related side effects." Conventional therapeutic antibodies are first developed in other species and then must undergo additional work to 'humanize' them. The antibody was generated using Harbour BioMed's H2L2 transgenic mouse technology.

"This is groundbreaking research," said Dr. Jingsong Wang, Founder, Chairman & Chief Executive Officer of HBM. "Much more work is needed to assess whether this antibody can protect or reduce the severity of disease in humans. We expect to advance development of the antibody with partners. We believe our technology can contribute to addressing this most urgent public health need and we are pursuing several other research avenues."

The paper is titled, "A human monoclonal antibody blocking SARS-VoV-2 Infection. In addition to Drs. Bosch and Grosveld, authors on the paper included: Chunyan Wang, Wentao Li and Frank van Kuppeveld of Utrecht University; Nisreen Okba and Bart Haagmans of Erasmus Medical Center (Rotterdam); Dubravka Drabek and Rien van Haperen of Erasmus Medical Center and Harbour Antibodies; and Albert Osterhaus of the University of Veterinary Medicine (Hannover, Germany).

 






Source: sciencedaily.com



Prev article
Next article

0 Comments

view all comments

Related

science news

Wuhan lockdown prevents 12-42 million people from catching COVID-19 295

science news

Chinese scientist who produced genetically altered babies sentenced to 3 years in jail 48

science news

China launches second trial space station 123

science news

DNA confirms cause of 1665 London's Great Plague 193

Gadget Reviews

Bevy photo-sharing device 222

Gadget Votes: 1 |5 out of 5
1/7/2016

Samsung's Family Hub Fridge 263

Gadget Votes: 1 |5 out of 5
1/7/2016

oombrella 250

Gadget Votes: 1 |3 out of 5
1/29/2016
View more articles

Tag Cloud

social politics business opinion sports education health technology religion extra science Classifieds Jobs

Photo Gallery

Send Email

Write a Comment


Resident Manager

All Ghana Data, P. O. Box Ah 9182, Ahinsan, Ashanti, Ghana
+233 27 872 7027
i-desk@allghanadata.com

Popular Articles

Idris Elba almost died in Ghana466

27 Nov 2015

Lucky Dube’s Daughter To Rock Ghana1686

16 Nov 2011
View more articles

Popular Categories

  • news
  • institutions
  • entertainment
  • blogs
  • recipes
  • classifieds

Random Selfies Feed

View Gallery
  • Home
  • Privacy
  • Classifieds
  • Lifestyle
  • Jobs
  • Sitemap
  • Contact us

©Copyright 2002-2021 All Ghana Data All Rights Reserved | Powered by SASCMS